Skip to main content Back to Top
Advertisement

2/23/2026

Epoprostenol Injection

Products Affected - Description

    • Flolan lyophilized powder for injection, GSK, 0.5 mg, single dose vial, NDC 00173-0517-00 - discontinued
    • Flolan lyophilized powder for injection, GSK, 1.5 mg, single dose vial, NDC 00173-0519-00 - discontinued
    • Epoprostenol sodium lyophilized powder for injection, Mylan (Viatris), 0.5 mg, single dose vial, NDC 67457-0587-10
    • Epoprostenol sodium lyophilized powder for injection, Mylan (Viatris), 1.5 mg, single dose vial, NDC 67457-0588-10
    • Epoprostenol sodium lyophilized powder for injection, Sun Pharma, 0.5 mg, single dose vial, NDC 62756-0059-40
    • Epoprostenol sodium lyophilized powder for injection, Sun Pharma, 1.5 mg, single dose vial, NDC 62756-0060-40

Reason for the Shortage

    • Actelion has Veletri available.
    • GlaxoSmithKline discontinued Flolan in November 2025.
    • Sun Pharma did not provide a reason for the shortage.
    • Viatris did not provide a reason for the shortage.

Available Products

    • Veletri lyophilized powder for injection, Actelion Pharmaceuticals, 0.5 mg, single dose vial, NDC 66215-0403-01
    • Veletri lyophilized powder for injection, Actelion Pharmaceuticals, 1.5 mg, single dose vial, NDC 66215-0402-01

Estimated Resupply Dates

    • Sun Pharma has epoprostenol 0.5 mg and 1.5 mg vials on back order and the company estimates a release date of mid-March 2026.
    • Viatris has epoprostenol 0.5 mg and 1.5 mg vials on back order and the company estimates a release date of late-June 2026 for the 0.5 mg vials and early- to mid-March 2026 for the 1.5 mg vials.

Updated

Created February 23, 2026 by Leslie Jensen, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT